Table SI. Relative baseline-to-treatment differences

	All biologics (%)	Difference among biologics (significance)			αTNF (%)	αIL12/23 (%)
	Median (IQR) (*n*) (sig.)[a]	Overall[b]	ADA vs. ETA[c]	TNFα vs. αIL12/23[c]	Median (IQR) (*n*) (sig.)[d]	Median (IQR) (*n*) (sig.)[d]
Leucocytes	−6.4 (−17; 4) (172) (0.000)**	(0.727)				
Neutrophils	−10.9 (−24; 4) (169) (0.000)**	(0.277)				
Lymphocytes	11.4 (−2; 31) (169) (0.000)**	(0.011)*	(0.272)	(0.005)**	12.6 (0; 13) (148) (0.000)**	0.0 (−16; 0) (21) (0.748)
Thrombocytes	−5.6 (−12; 1) (171) (0.000)**	(0.390)				
Haemoglobin	0.6 (−2; 3) (171) (0.098)	(0.141)				
Erythrocytes	0.6 (−2; 4) (171) (0.023)*	(0.818)				
C-reactive protein	0.0 (−36; 6) (172) (0.023)*	(0.252)				
LDH	0.0 (−6; 7) (169) (0.749)	(0.717)				
Triglycerides	9.4 (−12; 36) (139) (0.000)**					
Cholesterol	−0.9 (−5; 4) (138) (0.749)					
GOT	7.0 (−7; 22) (172) (0.000)**	(0.961)				
GPT	4.1 (−12; 24) (172) (0.006)**	(0.766)				
GGT	3.2 (−10; 19) (172) (0.017)*	(0.237)				
Blood urea nitrogen	4.7 (−5; 17) (172) (0.000)**	(0.597)				
Creatinine	4.0 (−2; 10) (172) (0.000)**	(0.583)				

*$p < 0.05$, **$p < 0.01$, [a]Wilcoxon signed-rank test corrected for false discoveries, [b]Kruskal-Wallis test, [c]Mann-Whitney *U* test, [d]Wilcoxon signed-rank test.
LDH: lactate dehydrogenase; GOT: glutamate-oxaloacetate transaminase; GPT: glutamate-pyruvate transaminase; GGT: gamma-glutamyl transferase; ADA: Adalimumab; ETA: Etanercept; TNFα: tumour necrosis factor-α; IL: interleukin.

Table SII. Detailed presentation of laboratory adverse events

CTCAE III–IV adverse event	Biologic	Occurrence (days)	Biologic regime altered	Comment
Neutropaenia	ADA	113	No	Once 0.6/nl, self-limited without treatment alteration.
Lymphocytopaenia	ADA	94	No	Once 0.2/nl, self-limited without treatment alteration.
	ADA	548	No	Once 0.3/nl, self-limited without treatment alteration.
Creatinine increase	ADA	274	No	Once 2.83 mg/dl, previously known chronic renal failure, baseline creatinine already at 2.34 mg/dl, concentration fell below CTCAE III° criteria without treatment alteration.
GOT increase	ETA	28	No	Once 293 U/l, fell to normal limits without treatment alteration, no known cause.
GPT increase	ADA	77	No	Two measurements of 251 and 252 U/l within a week, fell to normal limits afterwards without treatment alteration, no known cause.
	ADA	85	Yes	Continuous increase to 239 U/l, previously known hemochromatosis, treatment cessation in good skin condition.
	ADA	737	No	Once 239 U/l, concomitant MTX, fell to normal limits after cessation of MTX.
	ETA	531	No	Once 259 U/l, fell below 60 U/l without treatment alteration, no known cause.
GGT increase	ADA	15	No	Most GGT measurements above 200 U/l. S/p MTX. High alcohol intake.
	ADA	1,570	Yes	Once 325 U/l, subsequent diagnosis of hepatic metastases and treatment cessation.
	ETA	28	No	Repeatedly increased up to 904 U/l. 197 U/l at baseline. GPT max. 119 U/l, GOT max 101 U/l. S/p MTX. S/p alcohol abuse. HBV/HCV negative. Ultrasound and CT: hepatic steatosis. Liver biopsy refused. No known cause.
	ETA	28	No	Repeatedly increased up to 523 U/l, high alcohol intake.
	UST	57	No	Once 226 U/l, concomitant MTX, GGT dropped after reduction of MTX.
	UST	301	No	Repeatedly increased up to 402 U/l, high alcohol intake.

GOT: glutamate-oxaloacetate transaminase; GPT: glutamate-pyruvate transaminase; GGT: gamma-glutamyl transferase; ADA: Adalimumab; ETA: Etanercept; MTX: methotrexate; HBV/HCV: Hepatitis B virus/hepatitis C virus; S/p: status post.

Table SIII. Predictors of laboratory adverse events

Predictor	Odds ratio (95% CI)	Significance
Male sex	0.76 (0.22–2.60)	0.759
Age	1.01 (0.96–1.05)	0.723
Previous systemic treatments	0.96 (0.66–1.38)	0.821
Psoriatic arthritis	1.05 (0.33–3.31)	0.94

CI: confidence interval.